Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.10.008 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.10.008 33039612!7544564!33039612     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2020 ; 101 (ä): 382-390 Nephropedia Template TP {{tp|p=33039612|t=2020. Diagnostic performance of commercially available COVID-19 serology tests in Brazil |pdf=|usr=}}{{33039612}} gab.com Text Diagnostic performance of commercially available COVID-19 serology tests in Brazil JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33039612 #FOAvip Timely and accurate laboratory testing is essential for managing the global COVID-19 pandemic. Reverse transcription polymerase chain reaction remains the gold-standard for SARS-CoV-2 diagnosis, but several practical issues limit the test's use. Immunoassays have been indicated as an alternative for individual and mass testing. OBJECTIVES: To access the performance of 12 serological tests for COVID-19 diagnosis. METHODS: We conducted a blind evaluation of six lateral-flow immunoassays (LFIAs) and six enzyme-linked immunosorbent assays (ELISAs) commercially available in Brazil for detecting anti-SARS-CoV-2 antibodies. RESULTS: Considering patients with seven or more days of symptoms, the sensitivity ranged from 59.5% to 83.1% for LFIAs and from 50.7% to 92.6% for ELISAs. For both methods, the sensitivity increased with clinical severity and days of symptoms. The agreement among LFIAs performed with digital blood and serum was moderate. Specificity was, in general, higher for LFIAs than for ELISAs. Infectious diseases prevalent in the tropics, such as HIV, leishmaniasis, arboviruses, and malaria, represent conditions with the potential to cause false-positive results with these tests, which significantly compromises their specificity. CONCLUSION: The performance of immunoassays was only moderate, affected by the duration and clinical severity of the disease. Absence of discriminatory power between IgM/IgA and IgG has also been demonstrated, which prevents the use of acute-phase antibodies for decisions on social isolation. Twit Text FOAVip Diagnostic performance of commercially available COVID-19 serology tests in Brazil ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33039612 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33039612 #FOAvip English Wikipedia <ref>{{Cite pmid|33039612}}</ref> Diagnostic performance of commercially available COVID-19 serology tests in Brazil #MMPMID33039612 Cota G; Freire ML; de Souza CS; Pedras MJ; Saliba JW; Faria V; Alves LL; Rabello A; Avelar DM Int J Infect Dis 2020[Dec]; 101 (ä): 382-390 PMID33039612show ga Timely and accurate laboratory testing is essential for managing the global COVID-19 pandemic. Reverse transcription polymerase chain reaction remains the gold-standard for SARS-CoV-2 diagnosis, but several practical issues limit the test's use. Immunoassays have been indicated as an alternative for individual and mass testing. OBJECTIVES: To access the performance of 12 serological tests for COVID-19 diagnosis. METHODS: We conducted a blind evaluation of six lateral-flow immunoassays (LFIAs) and six enzyme-linked immunosorbent assays (ELISAs) commercially available in Brazil for detecting anti-SARS-CoV-2 antibodies. RESULTS: Considering patients with seven or more days of symptoms, the sensitivity ranged from 59.5% to 83.1% for LFIAs and from 50.7% to 92.6% for ELISAs. For both methods, the sensitivity increased with clinical severity and days of symptoms. The agreement among LFIAs performed with digital blood and serum was moderate. Specificity was, in general, higher for LFIAs than for ELISAs. Infectious diseases prevalent in the tropics, such as HIV, leishmaniasis, arboviruses, and malaria, represent conditions with the potential to cause false-positive results with these tests, which significantly compromises their specificity. CONCLUSION: The performance of immunoassays was only moderate, affected by the duration and clinical severity of the disease. Absence of discriminatory power between IgM/IgA and IgG has also been demonstrated, which prevents the use of acute-phase antibodies for decisions on social isolation. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/blood[MESH] |Brazil[MESH] |COVID-19/blood/*diagnosis/virology[MESH] |Coronavirus Infections/epidemiology[MESH] |Enzyme-Linked Immunosorbent Assay/economics/*methods[MESH] |Female[MESH] |Humans[MESH] |Immunoassay/economics/*methods[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |SARS-CoV-2/genetics/immunology/isolation & purification[MESH] |Sensitivity and Specificity[MESH]Diagnostic performance of commercially available COVID-19 serology tes(epmc).pdf DeepDyve Pubget Overpricing